|Bid||21.74 x 1200|
|Ask||23.00 x 900|
|Day's Range||20.80 - 21.94|
|52 Week Range||13.92 - 35.85|
|Beta (5Y Monthly)||0.05|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 04, 2021 - May 10, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||28.50|
SAN DIEGO, April 12, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced the appointment of Oleg Nodelman to the company’s Board of Directors. “Oleg is an experienced biotechnology company builder with deep insight in the development and financing of novel therapies,” said Hamza Suria, president and chief executive officer of AnaptysBio. “We welcome Oleg to our Board of Directors and look forward to his contributions to AnaptysBio’s capital-efficient antibody discovery and development business model.” “AnaptysBio has an impressive antibody development heritage that has led to the advancement of eight internally-generated novel therapeutics into clinical development,” commented Mr. Nodelman. “I look forward to working with the company’s Board and management team to advance AnaptysBio’s first-in-class wholly-owned antibody pipeline for inflammatory and immuno-oncology applications.” About AnaptysBioAnaptysBio is a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications. The Company’s proprietary anti-inflammatory pipeline includes its anti-IL-36R antibody imsidolimab, previously referred to as ANB019, for the treatment of rare inflammatory diseases, including generalized pustular psoriasis, or GPP, EGFRi skin toxicity, ichthyosis, hidradenitis suppurativa and acne; its anti-PD-1 agonist program, ANB030, for treatment of certain autoimmune diseases where immune checkpoint receptors are insufficiently activated; and its BTLA modulator program, ANB032, which is broadly applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. AnaptysBio’s antibody pipeline has been developed using its proprietary somatic hypermutation, or SHM platform, which uses in vitro SHM for antibody discovery and is designed to replicate key features of the human immune system to overcome the limitations of competing antibody discovery technologies. AnaptysBio has also developed multiple therapeutic antibodies in an immuno-oncology collaboration with GlaxoSmithKline, including an anti-PD-1 antagonist antibody (dostarlimab GSK4057190A), an anti-TIM-3 antagonist antibody (cobolimab, GSK4069889A) and an anti-LAG-3 antagonist antibody (GSK4074386), and an inflammation collaboration with Bristol-Myers Squibb, including an anti-PD-1 checkpoint agonist antibody (CC-90006) currently in clinical development. Contacts:Dennis MulroyAnaptysBio, Inc.firstname.lastname@example.org
Celebrations may be in order for AnaptysBio, Inc. ( NASDAQ:ANAB ) shareholders, with the analysts delivering a...
AnaptysBio Inc’s (NASDAQ: ANAB) stock seems attractive after the POPLAR data and the 30% selloff, while there are several catalysts over the next 12-18 months, according to Truist Securities. AnaptysBio is a clinical-stage biotechnology company developing first-in-class immunology therapeutic product candidates to patients, according to its website. The AnaptysBio Analyst: Joon Lee upgraded the rating for AnaptysBio from Hold to Buy, while raising the price target from $27 to $34. The AnaptysBio Thesis: The company is posed for value creation in 2021 and 2022, given the “rich pipeline from wholly-owned and partnered programs,” Lee said in the upgrade note. “Our due diligence suggest imsidolimab may have stronger rationale for EGFRi mediated skin toxicity with interim topline expected YE21. And GPP, for which ANAB is planning to start Ph3 mid-2021, may be a much larger indication than we currently model,” he wrote. “Also, we like the rich pipeline, including ANB030, a PD-1 agonist (LLY also has one) and ANB032, a BLTA modulator. Lastly, we raise ANAB floor based on updated milestone expectations from GSK collab,” the analyst said. ANAB Price Action: Shares of AnaptysBio had risen by 2.95% to $20.40 at the time of publication Tuesday. (Photo by Bill Oxford on Unsplash) Latest Ratings for ANAB DateFirmActionFromTo Mar 2021Truist SecuritiesUpgradesHoldBuy Mar 2021WedbushDowngradesOutperformNeutral Feb 2021JP MorganUpgradesUnderweightOverweight View More Analyst Ratings for ANAB View the Latest Analyst Ratings See more from BenzingaClick here for options trades from BenzingaWhy Advanced Micro Devices's EPYC3 Server Launch Impressed This AnalystHere's Why BofA Raised US Steel Target By 50%© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.